MacuLogix Seeks $5M of Series B Funds

MacuLogix, an ophthalmic diagnostics company based in Hummelstown, Pa., has announced it is aiming to raise $5 million in Series B funding, according to a DOWJONES report.

Advertisement

MacuLogix is seeking the funding for its macular degeneration early-detection tool.

More Articles on Ophthalmology:

Dr. Mary Green Honored as Sightpath Top Surgeon
Experimental Bausch + Lomb Glaucoma Treatment Proves Effective
National Eye Institute Funds $6.2M Macular Degeneration Study

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Ophthalmology

Advertisement

Comments are closed.